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Abstract
Activating BRAF mutations have been reported in 40% of papillary thyroid carcinomas (PTCs). The involvement
of BRAF pseudogene in thyroid tumorigenesis has not previously been studied. We investigated BRAF pseudo-
gene expression in 68 thyroid tumors: 16 multinodular goiters, 43 classic PTCs, 6 follicular variants of PTC, and
3 anaplastic thyroid carcinomas. BRAF pseudogene function was studied by Western blots, soft agar assay, and
tumorigenesis in nude mice. BRAF pseudogene expression was detected in 7 multinodular goiters, 18 classic PTC,
and 1 follicular variants of PTC. There is an inverse correlation between BRAF pseudogene expression and BRAF
mutation. The pseudogene transcripts were more frequently detected in tumors without BRAF mutation than
those with BRAF mutation. Furthermore, BRAF pseudogene expression could activate the MAP kinase signaling
pathway, transform NIH3T3 cells in vitro, and induce tumors in nude mice. These data suggest that BRAF pseudo-
gene activation may play a role in thyroid tumor development.
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Introduction
Papillary thyroid carcinomas (PTCs) are the most common type of
differentiated thyroid carcinomas, accounting for some 85% thyroid
malignancies [1]. The most common genetic events are involved in
RAS-RAF-MEK-ERK-MAPK signaling pathway such as RAS point
mutations, RET/PTC oncogenes, NTRK1 rearrangements (TRK),
and BRAF mutations [2–8]. BRAF is a serine/threonine kinase that
serves as an immediate downstream effector of RAS in the RAS-RAF-
MEK-ERK-MAPK signaling cascade. Oncogenic mutations in BRAF
are common in human cancers, nearly all of which are the T1799A
transversion in exon 15, resulting in a V600E substitution in the pro-
tein [9,10]. This mutation is believed to produce a constitutively ac-
tive kinase by disrupting hydrophobic interactions between residues
in the activation loop and residues in the ATP binding site [11,12].
Two human BRAF loci (B-raf-1 and B-raf-2) have been identified
[13]. B-raf-1 is located on chromosome 7q34 and encodes the func-
tional 94-kDa BRAF protein. B-raf-2 is located on chromosome
Xq13 and has been predicted to be an inactive processed pseudogene
owing to the presence of point mutations, insertions, and deletions
relative to B-raf-1, although its expression and function has not been
investigated yet [13].
Pseudogenes have a similar DNA sequence to their functional genes;
they are nonetheless unable to produce functional final protein pro-
ducts and have generally been considered as evolutionary “dead-
end.” They may originate from reverse transcription (RT) of normal
mRNA transcripts (processed pseudogenes) or from gene duplication
(nonprocessed pseudogenes) [14]. One of the interesting findings from
genome sequencing is the abundance of pseudogenes in mammalian
genomes: roughly the same number of pseudogenes as protein-coding
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genes in all mammals sequenced so far [15]. Now there is a growing
number of evidence suggesting that some of them may have active
regulatory roles [16–18].
In the present study, we investigated BRAF pseudogene expression
in 68 thyroid tumors from Saudi Arabia, its relationship with BRAF
mutation, and its association with clinical and pathological features
of PTC. The functional aspects of BRAF pseudogene expression were
also studied.
Materials and Methods
Thyroid Tumor Specimens
All tumor tissues were obtained at surgery and stored at −70°C
until processed. The clinical staging of thyroid cancer was based
on the TNM classification [19]. Sixty-eight thyroid tumors were
studied: 16 benign multinodular goiters, 43 classic PTCs, 6 follicular
variants of PTC, and 3 anaplastic thyroid carcinomas (ATCs). The
study was reviewed and approved by the institutional review board.
DNA Amplification and Sequence Analysis of Exon 15
of BRAF
Tumor DNA was extracted by standard proteinase-K treatment fol-
lowed by phenol/chloroform extraction. Exon 15 was amplified by
polymerase chain reaction (PCR) using the following two primers:
5′-TCATAATGCTTGCTCTGATAGGA-3′ and 5′-CTAGTAACT-
CAGCAGCATCTC-3′. The PCR conditions were 95°C for 10 min-
utes followed by 35 cycles of amplification (95°C for 1 minute, 54°C
for 1 minute, and 72°C for 1 minute). The resulting PCR products
were analyzed by gel electrophoresis. Each successfully amplified frag-
ment was directly sequenced using the BigDye Terminator V3.1 Cycle
Sequencing kit (Applied Biosystems, Foster City, CA).
Reverse Transcription–PCR Analysis of BRAF
Pseudogene Transcripts
Total RNA was extracted using the guanidinium thiocyanate–
phenol–chloroform method. To amplify BRAF pseudogene tran-
scripts, 2 μg of total RNA were first treated with DNase 1 (10 U
at 37°C for 30 minutes, heat inactivation at 70°C for 5 minutes) to
remove contaminating genomic DNA and then reverse-transcribed
into cDNA using Oligo dT–based reverse transcription system (Proems,
Madison, WI). Pseudogene transcripts were amplified by PCR using
the following two specific primers: 5′-CTTGTATTACCTTCTCCA-
TATA-3′ and 5′-CTAGACCAAAATCACCTATTTCC-3′. The se-
quences different from BRAF wild type gene were highlighted in
bold. Polymerase chain reaction conditions were the same as described
above. The resulting 185-bp PCR products were analyzed by gel
electrophoresis and were directly sequenced to confirm specificity of
pseudogene transcripts. To amplify BRAF transcripts covering exon 15,
the forward primer (based on exon 14: 5′-GCATGGATTACTTA-
CACGCCA-3′) and the reverse primer (based on exon 16: 5′-CAATT-
CATACAGAACAATCC-3′), were located in different exons to avoid
amplification of contaminating genomic DNA. This primer pair can
also amplify corresponding BRAF pseudogene transcripts.
Quantitative Real-time RT-PCR Analysis of BRAF Transcripts
Quantitative RT-PCR analysis was performed as described previ-
ously [20]. Briefly, total RNA were reverse-transcribed into cDNA.
LightCycler DNA Master SYBR Green kit was used for quantitative
PCR analysis (Roche, Mannheim, Germany). The cDNA mix was
diluted 10-fold, and 2 μl of the dilution was used for real-time PCR
analysis. BRAF-specific PCR primers for 216-bp cDNA fragment were
5′-CAAACTTATAGATATTGCACA-3′ (sense) and 5′-TCTGGT-
GCCATCCACAAAATG-3′ (antisense). The sequence different from
BRAF pseudogene was highlighted in bold, and the PCR primers span
intron 14 so that contaminating genomic DNA will not be amplified.
The mRNA level of housekeeping gene glyceraldehydes-3-phosphate
dehydrogenase (GAPDH ) was used as an internal control, and a
300-bp PCR product was amplified using the following two primers:
5′-ACAGTCAGCCGCATCTTCTT-3′ (sense) and 5′-TTGATTTT-
GGAGGGATCTCG-3′ (antisense). The PCR conditions were as fol-
lows: 95°C for 30 seconds followed by 35 cycles of amplification (95°C
for 5 seconds, 48°C for 5 seconds, and 72°C for 10 seconds). The re-
sulting concentrations of BRAF PCR products were normalized by
comparison with GAPDH and were used to determine the BRAF
mRNA level.
Cloning and Expression of BRAF–Wild Type, –V600E
Mutant, and –Pseudogene
The full-length BRAF–wild type and –V600E mutant cDNA were
amplified by RT-PCR from total RNA extracted from thyroid tissue
using the following primers: 5′-GACAGCGGCCGCTCGGGCCC-
3′ (sense), 5′-TCTCGGTTATAAGATGGCGGCG-3′ (sense, inter-
nal for nested PCR), and 5′-CCTGAACTCT CTCACTCATTTG-3
(antisense). The pseudogene cDNA was amplified by RT-PCR using
primers corresponding to exon 2 (5′-GTATGGAATATCAAACAAA-
TAA-3′) and 3′untranslated region of wild type BRAF: 5′-CCTGAA-
CTCTCTCACTCATTTG-3 (internal for nested PCR, antisense) and
5-TCCTTTTGTTGCTACTCTCCTG-3′ (antisense). The resulting
cDNA fragment was cloned into the expression vector pcDNA3.1,
which is under the control of the CMV promoter (Invitrogen, Carlsbad,
CA), and was verified by DNA sequencing with no mutation found.
All three constructs (pBRAFWT, pBRAFV600E, and pBRAFPSEUDO)
were transfected into CHO and NIH3T3 cells using Lipofectamine
(Invitrogen). Cells were selected in the presence of 400 μg/ml G418
for 3 weeks (Sigma, St. Louis, MO), and stable clones were pooled
for experiments. To detect protein expression of the pseudogene tran-
scripts, the coding sequence was amplified by PCR from the pseudo-
gene cDNA and cloned into a pcDNA3.1/V5-His expression vector
in frame with the V5 epitope at the C-terminus (Invitrogen), using
the following two primers: 5′-GGAACGGAACTGATTTTTCT
GTT-3′ (sense) and 5′-GTGATCTTCATCTGCTGGT CGGAA-3′
(antisense). The resulting plasmid (pBRAFPSEUDO-V5) was stably trans-
fected into CHO cells.
Western Blot Analysis
A total of 60 μg of protein from stably transfected CHO cells
(pBRAFPSEUDO-V5, pBRAFWT, pBRAFV600E, and pBRAFPSEUDO)
were loaded onto a 12% sodium dodecyl sulfate–polyacrylamide
gel. Proteins were transferred to a polyvinylidene fluoride membrane
and were subjected to Western blot analysis with anti-V5 monoclonal
antibody (1:5000 dilution; Invitrogen) or anti–total ERK 1/2
(1:2000 dilution) and anti–phospho-ERK 1/2 antibodies (1:1000;
Santa Cruz Biotechnology Inc., Santa Cruz, CA).
Quantification of MAP Kinase Activation by BRAF
Pseudogene in CHO Cells
pBRAFPSEUDO– and pBRAFPSEUDO-V5–transfected CHO cells
were cultured in serum-free medium for 16 hours. The cells were
58 BRAF Pseudogene Activation in Thyroid Tumor Zou et al. Neoplasia Vol. 11, No. 1, 2009
then stimulated with 20% fetal bovine serum for 2 hours in the pres-
ence or absence of 20 μM MEK inhibitor U0126 or BRAF inhibi-
tor SB590885 (EMD Chemicals, Inc., Gibbstown, NJ) for 2 hours.
The amount of cellular phospho-ERK 1/2 was measured using a
cell-based ELISA kit according to the manufacturer’s instructions
(SuperArray Bioscience Co., Frederick, MD).
Transformation Assays
A total of 2 × 104 stably transfected NIH3T3 cells (pBRAFWT,
pBRAFV600E, and pBRAFPSEUDO) were plated into a six-well cell
culture plate for an anchorage-independent growth by soft agar assay
according to the manufacturer’s instructions (Chemicon Interna-
tional, Temecula, CA). For in vivo transformation experiments, 1 ×
106 of stably pBRAFPSEUDO–transfected NIH3T3 cells were injected
subcutaneously into four female nude mice (The Jackson Laboratory,
Bar Harbor, ME). Mice were observed twice weekly and killed when
tumor reached 5 × 5 mm in size.
Results
BRAF Pseudogene Expression in Thyroid Tumors
Because BRAF pseudogene is a retrogene and has no intron, con-
taminating genomic DNA will be amplified by PCR from RNA prep-
arations. To eliminate genomic DNA contamination, RNA was first
digested with DNase 1 before being reverse-transcribed into cDNA.
The pseudogene transcripts were detected in 7 (43.8%) of 16 multi-
nodular goiters, 18 (41.9%) of 43 classic PTCs, and 1 (16.7%) of
6 follicular variants of PTC (FVPTCs; Figure 1 and Table 1). The
transcripts were not detected in five normal thyroid tissues (data not
shown). The transcripts were detected more frequently in tumors
without BRAF mutation (20/27, 74.4%) than those with BRAF mu-
tation (7/27, 25.9%; Table 1; P < .01, Fisher exact test). They were
Figure 1. Detection of BRAF pseudogene expression by RT-PCR
from thyroid tumor samples. A total of 2 μg of total RNA were first
treated with DNase 1 to remove contaminating genomic DNA and
then reverse-transcribed into cDNA. Pseudogene cDNA were am-
plified by PCR using specific primers. No amplification was seen
when RNA was used as a template. Representative results from
two cell lines and four samples were shown. Pseudogene tran-
scripts were detected as a 185-bp cDNA fragment from SW579
cell line, one goiter and two PTC samples.
Table 1. BRAF T1799A Mutation and Pseudogene Expression in Thyroid Carcinoma.
No. Diagnosis Age (year) Sex Stage BRAF T1799A
Mutation
BRAF Pseudogene
Expression
1 Goiter 35 F No No
2 Goiter 49 M No No
3 Goiter 40 F No Yes
4 Goiter 39 F No Yes
5 Goiter 38 F No Yes
6 Goiter 38 F No Yes
7 Goiter 30 F No No
8 Goiter 65 F No No
9 Goiter 31 F No No
10 Goiter 30 F No Yes
11 Goiter 38 F No Yes
12 Goiter 43 M No Yes
13 Goiter 60 F No No
14 Goiter 52 M No No
15 Goiter 21 F No No
16 Goiter 45 F No No
17 PTC 28 F I No No
18 PTC 40 M I No No
19 PTC 23 F I No No
20 PTC 48 F I No No
21 PTC 36 F I No No
22 PTC 36 F I No Yes
23 PTC 43 F I No Yes
24 PTC 18 M I No Yes
25 Metastatic PTC 33 F 1 No No
26 Metastatic PTC 24 F I No No
27 Metastatic PTC 35 F I Yes No
28 Metastatic PTC 26 F I No Yes
29 Metastatic PTC 36 F I Yes Yes
30 Metastatic PTC 22 F II No No
31 Metastatic PTC 41 F II Yes Yes
32 Metastatic PTC 12 F I No Yes
33 Metastatic PTC 40 F I Yes No
34 Metastatic PTC 32 F I No No
35 Metastatic PTC 24 F I No Yes
36 Metastatic PTC 30 F I Yes No
37 Metastatic PTC 25 F I Yes No
38 Metastatic PTC 37 F I No Yes
39 Metastatic PTC 26 M I No Yes
40 PTC 82 M II Yes Yes
41 PTC 57 F II Yes Yes
42 PTC 52 F II No Yes
43 Metastatic PTC* 27 F II No Yes
44 PTC 55 F III Yes Yes
45 PTC 46 M III No No
46 PTC 60 M III Yes No
47 PTC 58 F III No No
48 PTC 73 F III Yes No
49 PTC 72 F III No No
50 PTC 59 F III Yes No
51 PTC 50 M III Yes No
52 PTC 72 F III Yes No
53 PTC 66 M III Yes No
54 PTC 71 M IV No Yes
55 PTC 46 F IV Yes Yes
56 PTC 70 F IV Yes No
57 PTC 63 M IV Yes No
58 PTC 49 M IV Yes No
59 PTC 77 M IV Yes Yes
60 ATC 81 M IV Yes No
61 ATC 76 F IV Yes No
62 ATC 43 F IV Yes No
63 FVPTC 32 F I No No
64 FVPTC 34 F I No No
65 Metastatic FVPTC 21 F I No Yes
66 FVPTC 43 M I No No
67 FVPTC 68 F IV No No
68 FVPTC 45 F II No No
ARO cell line Yes No
NPA cell line Yes No
SW579 cell line No Yes
Metastatic PTC refers to stage I or II tumors with local lymph note metastasis.
*PTC-1 mutation was detected.
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also found more frequently in benign tumors and in early stages of
thyroid cancer (Figure 2A). By contrast, BRAF mutation is frequently
found in patients with stages III and IV tumors (P < .01; Figure 2B).
When using generic primers surrounding BRAF exon 15, wild type
and mutated T1799A BRAF transcripts could be detected together
with pseudogene transcripts by RT-PCR sequence analysis (Figure 3).
The pseudogene transcripts harbored several sequence variations
compared with wild type BRAF: T1794C (A1794A), C1807T
(R603X), C1848T (S616S), A1849T (I617F), G1857T (W619C),
C1894T (P632S), and G1915A (V639I) (Figure 3). If one overlooks
the existence of pseudogene expression, these sequence variations
could be mistakenly identified as BRAF mutations. However, these
sequence variations were not present in the matched genomic
DNA (Figure 3) because BRAF and its pseudogene are located on
chromosomes Xq13 and 7q34, respectively. Sequence analysis
showed that the pseudogene transcripts were more abundant than
wild type or mutant BRAF transcripts in some tumor samples, as
demonstrated by a single homozygous peak in the sequence chro-
matogram, whereas in other samples, heterozygous peaks could be
detected, showing both functional BRAF and BRAF pseudogene tran-
scripts (Figure 3).
To determine whether there is a correlation between BRAF gene ex-
pression and BRAF pseudogene expression, we performed quantitative
PCR comparing BRAF gene expression among normal, pseudogene-
positive, and pseudogene-negative tumor samples. As shown in Figure 4,
no correlation of BRAF expression was found between pseudogene-
positive and pseudogene-negative tumors. In pseudogene-positive
samples, the mean of BRAF/GAPDH ratio is 0.63 ± 0.43 compared
with 0.44 ± 0.14 in pseudogene-negative tumors (P > .05, Student’s
t test). These data suggest that BRAF pseudogene expression may not
regulate BRAF expression.
Activation of MAP Kinase by BRAF Pseudogene Expression
Analysis of the pseudogene cDNA sequence revealed that it has a
long open reading frame of 244 amino acids and corresponds to the
Figure 2. BRAF pseudogene expression in thyroid tumor speci-
mens. (A) Inverse association of BRAF pseudogene expression
with aggressiveness of PTC. The frequency of BRAF pseudogene
expression was reduced in advanced stages of thyroid carcinoma.
No BRAF pseudogene transcripts were detected in stage III PTC
samples. (B) Association of BRAF mutation with aggressiveness
of PTC. Higher frequency of V600E mutation was detected in ad-
vanced stages of thyroid carcinoma. Six FVPTC and three ATC
samples were included in the analysis. No mutation was detected
in the goiter.
Figure 3. Detection of BRAF pseudogene transcripts by sequencing
analysis of RT-PCR products. Three representative sequence chro-
matograms of matched DNA and RNA samples were shown. (A)
Presence of both BRAF wild type and pseudogene transcripts in
an RNA sample of multinodular goiter (no. 3 in Table 1). The pseudo-
gene transcripts presented as heterozygous mutations at T1794C
(A1794A) and C1807T (R603X), whereas matched DNA sample
did not show the mutations. (B) Detection of only BRAF pseudo-
gene transcripts in an RNA sample of multinodular goiter (no. 4 in
Table 1). The pseudogene transcripts presented as homozygous
mutations at T1794C (A1794A) and C1807T (R603X), whereas
matched DNA sample did not show the mutations. (C) Presence
of both BRAF mutant and pseudogene transcripts in an RNA sam-
ple of PTC (no. 44 in Table 1). The pseudogene transcripts presented
as heterozygous mutations at T1794C (A1794A) and C1807T
(R603X). Heterozygous T to A BRAF mutation was detected at
nucleotide 1799 and was confirmed in the matched DNA sample.
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wild type CR1 domain (Figure 5), which has been shown to mediate
autoinhibition of the C-terminal protein kinase domain (CR3) [21].
Amino acid sequence alignment between wild type BRAF and its
pseudogene showed 85.7% homology, suggesting that they may in-
teract with each other resulting in modulation of the MAP kinase
signaling pathway. To further investigate the functional role of BRAF
pseudogene expression, we cloned and expressed the pseudogene in
both CHO and NIH3T3 cells. As shown in Figure 6A, BRAF pseudo-
gene expression could activate MAP kinase in CHO cells. Similar
results were also found in NIH3T3 cells. We next quantified MAP
kinase activation by measuring phospho-ERK in BRAF pseudogene
(full-length) and N-terminal part of BRAF pseudogene–transfected
CHO cells. As shown in Figure 6B, both BRAF pseudogene and
N-terminal part of BRAF pseudogene could induce a higher level of
MAP kinase activation in the absence of serum stimulation. Both
MEK inhibitor U0126 and BRAF inhibitor SB590885 could reduce
the kinase activation by more than 70%. These data suggest that
BRAF pseudogene could lead to constitutive MAP kinase activation
through interaction with wild type BRAF and MEK, likely through
Figure 4. Real-time RT-PCR analysis of BRAF mRNA among nor-
mal, BRAF pseudogene-positive, and pseudogene-negative thyroid
tumor samples. BRAF transcripts were quantified and normalized
by comparison with GAPDH. Data are expressed as ratio of
BRAF/GAPDH mRNA among different groups. Because GAPDH
mRNA is more abundant than BRAF, log scale is used.
Figure 5. (A) Schematic representation of human BRAF gene and its pseudogene in scale. Each BRAF exon is indicated by its number
inside the boxes. The three conserved regions of the protein with the ARAF and RAF-1 genes are indicated by CR1, CR2, and CR3,
respectively. Ras binding domain (RBD), cysteine-rich domain (CRD), and kinase domain (KD) are indicated by three bars. G-loop is a
conserved glycine motif in exon 11, and AS is the activation segment in exon 15. Black arrows indicate the major phosphorylation sites
of the protein. The longest open reading frame of BRAF pseudogene is indicated by a black box and corresponds to wild type CR1
region, which plays a regulative role in kinase activity. (B) Amino acid sequence alignment between wild type BRAF and its pseudogene.
Sequence difference is highlighted in bold. There are a total of 244 amino acids in the pseudogene coding region, and only 35 amino
acid difference compared with wild type (85.68% homology).
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the N-terminal part of BRAF pseudogene. For confirmation that pseudo-
gene transcripts could be translated into protein, we cloned the
potential pseudogene coding sequence (244 amino acids N-terminus)
into a pcDNA3.1/V5 expression vector in frame with the V5 epitope
tag (pBRAFPSEUDO-V5). Using V5 monoclonal antibody, we were able
to detect a predicted 32-kDa protein in CHO cells stably transfected
with the vector, whereas no protein was detected in CHO cells trans-
fected with vector alone (Figure 6C ).
The transformation potential of BRAF pseudogene was assessed
in vitro by a soft agar assay in pBRAFPSEUDO–transfected NIH3T3
and CHO cells and in vivo by subcutaneous injection of stably
pBRAFPSEUDO–transfected NIH3T3 cells into four nude mice. As
shown in Figure 7, A and B, the soft agar assay resulted in six-fold
increases in the number of colonies from pBRAFPSEUDO–transfected
NIH3T3 cells and a four-fold increase from pBRAFPSEUDO–transfected
CHO cells, respectively. All four nude mice developed tumors
within 2 weeks after injection of 1 × 106 pBRAFPSEUDO–transfected
NIH3T3 cells.
Discussion
In the present study, we reported BRAF pseudogene expression in
thyroid tumors, which could transactivate MAP kinase and induce
tumors in nude mice. Furthermore, reciprocal BRAF mutation and
its pseudogene expression were also demonstrated.
BRAF pseudogene is a processed pseudogene that arises by retro-
transposition. In the process of retrotransposition, a portion of the
mRNA transcript of a gene is spontaneously reverse-transcribed
Figure 6. (A) Activation of MAP kinase by BRAF pseudogene. Chinese hamster ovary cells were stably transfected by pBRAFWT,
pBRAFV600E, or pBRAFPSEUDO, respectively. A total of 60 μg of proteins from each cell lysate were used for Western blot analysis.
Two blots with identical amount of protein loading were probed with antibodies to phospho-ERK 1/2 (pERK, indicating MAP kinase
activation) and total ERK 1/2 (for monitoring protein loading), respectively. (B) Quantification of MAP kinase activation by BRAF pseudo-
gene and N-terminal part of BRAF pseudogene (pBRAFPSEUDO-V5) in CHO cells. pBRAFPSEUDO– and pBRAFPSEUDO-V5–transfected CHO
cells were cultured in serum-free medium for 16 hours. The cells were then stimulated with 20% fetal bovine serum for 2 hours in the
presence or absence of 20 μM MEK inhibitor U0126 or BRAF inhibitor SB590885. The amount of phospho-ERK in the cells was mea-
sured using a cell-based ELISA kit at OD 450 nm and was normalized by dividing the OD 595 nm readings of relative cell number. Data
are expressed as means ± SEM of two separate experiments. (C) Protein expression of BRAF pseudogene. The putative BRAF pseudo-
gene coding region of 244 amino acids was cloned into a pcDNA3.1/V5-His vector (pBRAFPSEUDO-V5) and was expressed as a fusion
protein with a V5 epitope tag at the C-terminus in CHO cells. The expected 32-kDa fusion protein was detected by Western blot using V5
monoclonal antibody (lane 1). No protein was detected when CHO cells were transfected with a pcDNA3.1/V5-His vector alone (lane 2).
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back into DNA and inserted into chromosomal DNA. Because it is
derived from a mature mRNA product, a processed pseudogene lacks
introns and the upstream promoter of a normal gene and is thus con-
sidered “dead on arrival.” Pseudogenes also have many genetic
alterations such as point mutations, deletions, and insertions com-
pared to their normal genes [22]. However, many exceptions exist
where a pseudogene can be transcribed and even translated into an
active protein [22–28]. Indeed, BRAF pseudogene produces mRNA
transcripts that have many stop codons and cannot be translated into
a functional, full-length protein. The longest open reading frame can
only produce a polypeptide of 244 amino acids. This polypeptide
has no kinase domain and, therefore, cannot be functional by itself.
However, expression of BRAF pseudogene in some thyroid tumors
suggests that it may play a role in thyroid tumor development.
The functional studies confirmed that the BRAF pseudogene plays
an oncogenic role in thyroid tumorigenesis by transactivating the
MAP kinase pathway, likely through wild type BRAF, because BRAF
inhibitor abolishes its effect. Given the high sequence homology be-
tween the CR1 domain of wild type BRAF and its pseudogene, it is
likely that the BRAF pseudogene peptide interacts with the CR1
domain of wild type BRAF and interferes with its normal physiologic
role of negatively autoregulating its C-terminal protein kinase domain.
Hitotsune et al. [29,30] demonstrated that an expressed pseudogene
Mkrn1-p1 could regulate the expression of its homologous functional
coding gene by modulating messenger RNA stability. However, their
results have been challenged recently by Gray et al. [31], who showed
that theMkrn1-p1 pseudogene is neither expressed nor imprinted, nor
does it transregulate its source gene. Apparently, the contradictory re-
ports remain to be settled.
There is an inverse correlation between BRAF pseudogene activa-
tion and BRAF mutation in thyroid tumors. BRAF pseudogene tran-
scripts are more frequently detected in benign goiters and early stages
Figure 7. (A) Anchorage-independent growth of NIH3T3 and CHO cells stably transfected by pBRAFWT, pBRAFV600E, or pBRAFPSEUDO,
respectively. A total of 2 × 104 cells in 0.4% soft agar were cultured in duplicate in a six-well cell culture plate for 28 days. The colo-
nies were stained and counted. The results are the average number of colonies per well from four wells. (B) Representative results of
colony formation of NIH3T3 cells or CHO cells stably transfected by pBRAFWT, pBRAFV600E, or pBRAFPSEUDO, respectively. Original
magnification, ×40.
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of thyroid cancer. It becomes silenced in late stages of cancer, espe-
cially when BRAF mutation is present, suggesting that only one
of the events is enough to drive oncogenic transformation of nor-
mal thyroid epithelial cells. A previous study by Zhang et al. [32]
showed that PTEN pseudogene expression might play a pathologi-
cal role in glioblastomas and was complementary to PTEN muta-
tion. In 14 of 18 glioblastomas, either PTEN mutation or PTEN
pseudogene expression was found, and only one case showed both
PTEN mutation and pseudogene expression. Their study reported
similar observations to the current study, that is, BRAF or PTEN
pseudogene expression could act as an alternative to BRAF or PTEN
mutation [32].
The high frequency of BRAF pseudogene expression in benign
goiters suggests that it may play a role in initiating goiter formation
or that a subset of goiters may contain precursor lesions such as
BRAF pseudogene expression, which may progress to malignancy
in the context of additional genetic or environmental factors. Recent
studies suggest that there may be abnormal BRAF in precursor lesions
and BRAFE600 contributes to the formation of some benign lesions
[33]. Our data suggest that the RAS-RAF-MEK-ERK-MAP kinase-
signaling cascade may be involved in some benign thyroid goiters
(43.8% in our study). Because the female-to-male ratio in thyroid
epithelial cell tumors is 3:1, one may wonder whether BRAF pseudo-
gene location on chromosome Xq13 contributes to this difference,
although in female mammals, most genes on one X chromosome
are silenced because of X-chromosome inactivation to achieve dosage
compensation between males and females. However, recent studies
have shown that some genes can escape X-inactivation and are ex-
pressed from both the active and inactive X chromosomes [34–
36]. BRAF pseudogene may escape X-inactivation and remains active
in some thyroid tumors. Further studies are needed to confirm this
speculation. Finally, BRAF pseudogene expression in a subset of
goiters may also have significant clinical implications. These pa-
tients may need to be followed up more closely for early sign of can-
cer development.
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